RAS-targeted therapies for pancreatic cancer
L.L. Chan, T.T. Kwong, J.C.W. Yau, S.L. Chan · 2026
Read RAS-targeted therapies for pancreatic cancer by L.L. Chan, T.T. Kwong, J.C.W. Yau, S.L. Chan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13578390.txt.
Description
Chan and co-authors review targeted drugs for pancreatic cancer in a 2026 survey. The cancer is driven by a stuck growth switch and fares poorly, and plain chemo has long stayed the main care while other cancers gained targeted drugs.
For decades the switch looked undruggable, with no pocket for a drug to grip. A found pocket changed that, and blockers for one switch form now control tumors in set cancers. A broad switch blocker more than doubled survival over chemo in a recent trial for treated patients. The review maps the new field and the hurdles ahead.
Catalog record
| CREATOR | L.L. Chan, T.T. Kwong, J.C.W. Yau, S.L. Chan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |